Dbv Technologies S.A. Sponsored ADR (DBVT)
NASDAQ (CM) NASDAQ (CM) Primary 
XFRA 
DBV Technologies: Regulatory Noise, Commercial Misperception, And A Deep Valuation Gap
DBV Technologies is rated Buy following positive Phase 3 VITESSE results. My risk- and dilution-adjusted DCF yields $42 per ADS, more than double the current share price. The model assumes that 60% of diagnosed children with adequate insurance coverage ultimately initiate treatment, reflecting Viaskin's favorable safety profile, user-friendly administration, and the significant burden of avoidance-only management. An initial backlog of untreated children creates a temporary annual revenue peak above $1.6bn before revenues stabilize around $1bn as the market reaches steady state.
DBV Technologies: Viaskin's FDA Path Still Leaves Room For More Upside
DBV Technologies is rated a buy, with a 24% upside to a $17 FY 2027 price target as Viaskin nears BLA submission. DBVT's transition from research to commercial readiness is evident, with rising sales/marketing spend and declining research tax credits signaling operational progress. The key catalyst is the planned Q3 2026 BLA submission, expected to trigger a 10-month FDA review and potential commercial launch in 2027.
DBV Technologies S.A. (DBVT) Q2 2026 Earnings Call Transcript
DBV Technologies S.A. (DBVT) Q2 2026 Earnings Call Transcript
DBV Technologies Q2 Earnings Call Highlights
DBV Technologies NASDAQ: DBVT said it is continuing preparations for a planned third-quarter 2026 Biologics License Application submission for its VIASKIN Peanut Patch in children ages 4 through 7, while also building commercial infrastructure ahead of a potential U.S. launch.
DBV Technologies S.A. (DBVT) Discusses Regulatory Update and FDA Interactions for Viaskin Peanut Patch in Young Children Transcript
DBV Technologies S.A. (DBVT) Discusses Regulatory Update and FDA Interactions for Viaskin Peanut Patch in Young Children Transcript
DBV Technologies (DBVT) Soars 5.3%: Is Further Upside Left in the Stock?
DBV Technologies (DBVT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
DBV Technologies: A Cohort-Driven Model That Could Support Blockbuster VIASKIN Revenue
DBV Technologies S.A. (DBVT) reported positive Phase 3 VITESSE results for Viaskin Peanut, advancing toward blockbuster sales projections exceeding $2 billion. My model estimates Viaskin Peanut's U.S. peak sales at $1.25 billion, with global revenues potentially reaching $2.1 billion, assuming central penetration and duration metrics. Current DBVT market valuation (~$2 billion) implies either lower peak sales or higher perceived risk versus a risk-adjusted valuation near $5 billion.
DBV Technologies (DBVT) Upgraded to Buy: What Does It Mean for the Stock?
DBV Technologies (DBVT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Wall Street Analysts Predict a 79.04% Upside in DBV Technologies (DBVT): Here's What You Should Know
The mean of analysts' price targets for DBV Technologies (DBVT) points to a 79% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
DBV Technologies (NASDAQ:DBVT) Shares Gap Up – Here’s What Happened
DBV Technologies S.A. (NASDAQ: DBVT - Get Free Report)'s share price gapped up before the market opened on Friday. The stock had previously closed at $20.06, but opened at $21.49. DBV Technologies shares last traded at $20.80, with a volume of 110,344 shares trading hands. Analyst Ratings Changes DBVT has been the subject of a
DBV Technologies S.A. (DBVT) Discusses Positive Phase III VITESSE Trial Results for Peanut Allergy Patch in Young Children Transcript
DBV Technologies S.A. (DBVT) Discusses Positive Phase III VITESSE Trial Results for Peanut Allergy Patch in Young Children Transcript
Is DBV Technologies (DBVT) Stock Outpacing Its Medical Peers This Year?
Here is how DBV Technologies S.A. (DBVT) and Aquestive Therapeutics (AQST) have performed compared to their sector so far this year.
